2nd Quarter 2014

Earnings Presentation

July 28, 2014

Disclaimer

This document contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. These forward-looking statements substantially depend on changing market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.
In addition, unaudited information herein reflects management's interpretation of information taken from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, these additional points and data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the results reported herein. No data or interpretative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.
Our management is not responsible for compliance or accuracy of the management financial data discussed in this report, which must be considered as for informational purposes only, and should not override the analysis of our audited consolidated financial statements for purposes of a decision to invest in our stock, or for any other purpose.

Organic Growth 2Q14 Net Revenue

(R$ Million)

1,133

468

Consumer

(R$ Million)

4.1%

487

1,069

6.0%

2Q13 2Q14

Pharma

(R$ Million)

601

7.4%

646

2Q13 2Q14

2Q13 2Q14

3

Gross Margin & Expenses 2Q14 Gross Margin

(%)

SG&A ex-marketing

(%)

Marketing

(%)

65.8%

0.2 p.p.

65.6%

23.0%

1.0 p.p.

22.0%

20.0%

0.3 p.p.

19.7%

2Q13 2Q14

2Q13 2Q14

2Q13 2Q14

4

Operating Results 2Q14 Adjusted EBITDA

(R$ Million)

288

Adjusted EBITDA Margin

(%)

25.4%

%RL

Net Income

(R$ Million)

1.8% 10.8%

258

11.5%

24.1%

1.3 p.p.

122

19

2Q13 2Q14

2Q13 2Q14

2Q13 2Q14

5

Cash Flow 2Q14 Operating Cash Flow

(R$ Million)

Free Cash Flow

(R$ Million)

%NR

13.1% 16.3%

%NR 8.8% 14.1%

185

159

94

2Q13 2Q14

2Q13 2Q14

6

Leverage*

4.0x 4.0x

3.5x

3.1x

2.9x

3.0x

2.9x

2.8x

2.7x

2.6x

1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14

*Net Debt / Adjusted EBITDA (last 12 months) 7

distributed by